

June 26, 2017
Market Strategies Newsletter Sample Issue

MARKET STRATEGIES NEWSLETTER

Where To Invest Newsletter

Balanced Investing Strategies To Make Money In Up Or Down Markets

A Publication of Princeton Research, Inc. (www.PrincetonResearch.com)
Contributing Staff: Michael King, Charles Moskowitz



A Sample of the Where To Invest Now Newsletter
Information Our Members Get Follows

Investing Trade Alerts
Charles Moskowitz Discussion

Gains On Closed Trades The Week \$ 295

2017 YTD Profits \$ 8211

Over 82% Returns

Open Positions:

Long 10 SPY June 30th 243 Calls

Funds in Use \$ 505.00

Charles Moskowitz Discussion

Week 25 was a slow week for my trading but the \$295 came from the day trades made on Friday. Year to date gains now total \$8211 and we have only one open trade in the SPY June 30th \$243 calls @ \$1.01, using only \$505.

The week was a study in the rotation that we've been discussing for the last several months. We went from the Financials to the "FANG" stocks and now we're now focused on all the sectors involved in Healthcare. These include hospitals, pharma, as well as drugs and the insurers. The IBB (biotech ETF) has finally broken out of an extended consolidation. The last time we had this type occurred in late 2011 and went on a run that lasted 4 years and from \$100 to \$400.

Most of the Sunday morning shows harped on the partisan nature of the current discussions on healthcare. This is no surprise but the one fallacy that sticks out is the same people complaining about the Republicans not addressing the issue had control for 8 years and what did they do? It's easy to blame those in power, but at some point the minds must meet.

One of the big problems this week was the move lower in oil. The move from \$52 to \$42 in roughly 17 trading days speaks volumes. While the cheating on production is to be expected, the magnitude is even greater than thought. The economic need for public works and infrastructure seems to be unrelenting and the need to sell even at weak prices has become evident. Even the Saudi political shake up is all about the need for less reliance on oil. The gold held its' low-end of the Bollinger Bands around \$1240 and looks like it can challenge 1270-80 anytime.

Market sentiment has not changed much this week with only nominal moves giving no real directional bias. Usually we have market internals to help but they were up one day down the next with nothing excessive in either direction.

From a technical point of view the S&P 500 is continuing to exhibit strength. If you'd like to see my technical opinion just use the link below to see a short and to the point video: You may need to copy and paste the address in your address line.

https://www.youtube.com/watch?v=1vd8_RRWbT8&feature=youtu.be

I'm sure you'll find it helpful. I will continue to trade the SPY options until the volatility picks up, since the premiums remain low...*CAM*

Investing Trade Alerts Summary **\$10,000 Trading Account Trade Table**

DATE	TRADES	PRICE	COST	PROCEEDS	RESULTS
06/23	Bought 5 SPY June 30 th 243 Calls	1.01	505		
06/23	Sold 10 SPY June 23 rd 242.50 Puts-expired worthless	0.27	000	270	270 Gain
06/23	Sold 5 SPY June 23 rd 243 Calls	0.39		195	115 Gain
06/23	Sold 5 SPY June 23 rd 243 Calls	0.50		250	170 Gain

06/23	Bought 10 SPY June 23 rd 243 Calls	0.16	160		
06/22	Sold 10 SPY June 243.50 Calls	0.30		300	20 Loss
06/22	Bought 10 SPY June 243.50 Calls	0.32	320		
06/19	Sold 6 TJX July 75 Calls	0.45		270	240 Loss
06/14	Bought 6 TJX July 75 Calls	0.85	510		

3rd Week expiration when the month is listed without a date

Previous closed out trades not listed here may be seen in previous market letters in the VIP Subscribers Members Area.

**Remember, these trades are based on your participation in the
Subscriber Members Only
TEXTING SERVICE TO RECEIVE ALL UPDATES.**

NOTE: In texting we have a limited amount of words. In the interest of brevity:

The Quantity and Strike Price for each trade is specific. 1=January, 2=February

Trading is hypothetical. We may trade weekly options and they are noted: SPY 1/25 147 for SPY Jan 25th 147 Calls or Puts.

Proven Trading Success

Our Recent [WINNING TRADES](#)

Our Recent WINNING TRADES

**178% Gains on SPY Calls in 1 Day
55% Gains on SPY Calls in 2 Days
485% Gains on SIG Calls in 10 Days
134% Gains on SIG Calls in 7 Days
91% Gains on SPY Calls in 6 Days
100% Gains on SPY Calls in 2 Days
112% Gains on SLM Calls in 31 Days
226% Gains on SPY Calls in 2 Days
125% Gains on SPY Calls in 2 Days
100% Gains on SPY Puts in 1 Day
57% Gains on JBLU Calls in 8 Days**

18% Gains on SPY Calls in 1 Day
91% Gains on SPY Calls in 1 Day
63% Gains on SPY Calls in 2 Days
100% Gains on SPY Calls in 1 Day
175% Gains on SPY Puts in 3 Days
57% Gains on JBLU Calls in 8 Days

See all trades in past newsletter issues.

Remember, these trades are based on your participation in the
Subscriber Members Only
TEXTING SERVICE TO RECEIVE ALL UPDATES.

New Trades Will Be TEXTED To MEMBERS

TRADE ALERTS

For Free Where To Invest Your Money Now
High Return Investments Trade Alerts
Go To: PrincetonResearch.com/alerts.htm

SPECIAL RATES Available for VIP MEMBERSHIP

Get the [lowest full membership rates available](#).

NOTE: This is a Sample Issue Only!
TO GET OUR TRADE ALERTS BY TEXT MESSAGE AND
THE COMPLETE VIP MEMBERS ONLY MARKET STRATEGIES NEWSLETTER ISSUES
Visit: PrincetonResearch.com/join.htm

Follow Our Marketed Weathered,
Time Tested Trading Rules That
PROTECT YOUR CAPITAL And SECURE PROFITS

Now you can profit from investing trade alerts from our traders with over 75 combined years of successful investing experience.

- [Make Money In Up Or Down Markets](#) -- Our trading alerts balanced investing strategies are designed and proven to make money in up or down markets.

- **Done For You** - All the stock options picking, research and trading analysis is done for subscribers. This is not a 'class' or a 'training course'... this is us doing ALL the work... from research to sending you a text on what to trade, along with recommended amounts...
- **SAFETY** - We strictly follow our **Tested, Market Weathered Trading Rules** that are proven time and time again to protect our (and now your) investment capital from losses while effectively allowing us to **Keep The Profits We Make**.

So even though we trade options to get the profits you see above -- We can do it with minimal risk and Maximum Profit Potential.

You Don't Need To Learn Any Trading Skills Or Do Any Time Consuming Analysis and Tracking

+++ We DO IT ALL FOR YOU! +++

We tell you where, when and how much to trade and you get to sit back and enjoy the rewards!

The specific buy and sell trading alerts are sent directly to you by e-mail and text message. So you can get in on and cash out on our winning trades fast and at the right time.

Get Started with Any Amount - Follow our recommended trading guidelines for a \$10,000 portfolio or invest more or invest less -- Whatever you are comfortable with. Your investment is protected because Time Tested Trading Rules PROTECT YOUR CAPITAL And KEEP YOUR PROFITS.

Join Us Today.

Lock in the [Lowest Membership Rates Available HERE](#)



2 FOR 1 BONUS:

Your Membership includes access to both:

**Trade Alerts by Text Message and e-mail
AND
The Market Investing Strategies Newsletter
Full Members Only Edition**

Our Where To Invest Now For Profits In Up or Down Markets Newsletter is more compact, informative, effective and quicker to read than the major, big name publications. AND there are NO ADS to wade through.

The Members Edition Newsletter is sent to you by e-mail Monday Mornings and available in the Members Area along with our archive of past issues.

SPECIAL RATES Available for VIP MEMBERSHIP

Get the **lowest full membership rates available.**

Market Strategies Technical Information

	SUPPORT	RESISTANCE
S&P 500	2416	2490
NASDAQ (QQQ)	137.60	144.00
Trans	9225	9490
DOW	20,990	21,360
TLT	124.70	127.80

The suggested QQQ resistance at 143.50 held last week; higher levels became euphoric.

Fundamental Analysis Stocks To Buy with Stops

Using fundamentals the following are stocks to trade hypothetically. They have done well. We have taken numerous profits as indicated on the table below. In addition many have been stopped out with small losses. All indicated on the table below. Balance is critical.

Alibaba has made a few points. We are raising the stop loss price.

We have no position in Alcoa AA. If long use the 50 day price m.a. as a risk point.

Flushing Financial FFIC fell to and held the 50 day price moving average on March 3rd, which was a buying opportunity. We would buy the Flushing Financial.

We have been correct on Boeing calling for \$ 200; Boeing is on its way to \$ 240.

We are not involved with Bristol Myers.

Hecla Mining is a buy as long as it is above the 13 day price moving average.

We took profits on ENZ but still want to buy at lower prices.

The HDGE is finally relevant at this time. It is a decent long as long as it holds above its 50 day price moving average.

Symbol	Name	Business Description	PE	P/S	MV mln	Price	Buy or Sell Limit	Stop Loss Or offset
BABA	Alibaba	China; more of a retailer than Amazon	50.67	13.21	275.5B	143.01	Bought @ \$ 111 on 4/7/17 opening	121x
AMZN	Amazon	Catalog & Mail Order	189	2.90	394B	1003.74 Long	Sell on stop	976x
SIMO	Silicon Motion	Semiconductor solutions for mobile storage and communications	9.7	2.5	1.39B	50.24	Bought 39.10 01/28/17	49.40x
CIO	City Office REIT	Real Estate Investment Trust high quality Offices	292	5.8	396Mln	12.72	Re Bought at 12.12	11.50x
TPC	Tutor Perini	Construction	12	0.25	1.3B	27.20 Stopped out 28.90 05/04	19.40 10/31/16	Looking for place to buy
SAVE	Spirit Airlines	Discount Airline	13	1.6	3.6B	52.55	48.10	Buy on a dip to \$ 52 or close above \$54.40
BMJ	Bristol Myers	Biopharmaceutical Products	28	5.1	94.9B	56.64 No position	Sold at 52.80x	Has no direction
BA	Boeing	Aerospace, commercial jetliners, military systems	14	0.85	81B	202.23	Long at 132 10/04/16	New stop loss at \$ 195
HL	Hecla Mining	Basic Materials	44	3.61	1.7B	5.32 Look for re-entry	Long at 5.30 5/5/17	A good long
FFIC	Flushing Financial	Bank Holding company Savings and loans	13	3,5	592Mln	27.68	19.10 06/27	50 day m.a. at 27.45
AA	Alcoa	Aluminum Processing and Technology	N/A	0.4	9.5B	31.09	21.15 originally bought 2/8/16	\$ 28.90-29.10 support

ENZ	Enzo Biochem	Life Sciences	NA	1.35	134M	11.54	Bought at 5.13 10/7/16	<i>Sold on Opening Monday 4/3/17 Sold 8.43</i>
BAC	Bank of America	Commercial Bank	10	2.02	165.3B	22.82	Bought at 15.42 9/30/16	23.60x stopped out on 3/21/17
HDGE	Advisor Shares	Ranger Bear ETF				8.69	<i>Stopped out on 5/24</i>	Must close above 8.85 to be long

\$100,000 Trading Portfolio Stock Positions and Trades

Each stock is allocated a theoretical \$ 5,000 share of the portfolio unless otherwise indicated.

Symbol	Purchase Price	Purchase Date	Stop/Loss	Price/Date Sold	Profit/(Loss)
OILU 200	16.42	06/20		16.84 06/21	\$ 84
BBRY 400	11.21	06/07			
OILU 150	19.67	06/07		20.48 06/13	\$ 121
GLYC 400	12.66	06/01			
HL 500	5.72	06/01			
GSAT 1500	2.30	05/18			
SLV 300	15.78	05/15			
AGQ 150	40.39	04/07			
NUGT 75	35.68	03/13			
RWM 100	50.60	11/21			
SPXU 200	22.88	11/14			
AMBA 100	63.75	10/13			
MOS 200	27.53	05/02			
EYES 500	5.04	04/04			
EYES 1000	6.49	12/28			
TWTR 200	28.51	10/28			
MOS 100	43.55	08/14			
HL 500	3.95	05/03			
SAN 600	8.40	12/16			
TEXQY 200	6.56	7/11			
REPR* 5000	0.22	10/22/12			

Recommendations will be both listed in this letter and texted to members.

Previous closed out stock and option positions can be found in past Market Strategies Newsletter issues available in the VIP Subscribers Members Area.

For those of you who do not buy puts to protect your portfolio, there are many ETF's that are the inverse of the DOW. The symbols are **DOG, DXD, SDS, TZA and RWM**, which go up when the DOW, S&P 500 and Russell 2000 go **down and down when they go up. The DZZ goes up double when gold goes down.**

Market Strategies \$100,000 Trading Account

There were four closed out options positions last week; three were offset by trading and one expired worthless. The net was a weekly gain of \$ 590.

The options expire on the third Friday of each Month unless otherwise posted.

The Stock table has the following 19 positions:

AGQ, AMBA, BBRY, EYES (2), GLYC, GSAT, HL (2), MOS (2), NUGT, REPR, RWM, SAN, SLV, SPXU, TEXQY, TWTR

The options call for a \$ 2,500 investment unless otherwise stated; each stock position requires \$5,000 unless otherwise mentioned specifically.

Money management is based on a hypothetical \$ 100,000.

The 19 stock positions would cost \$ 79,338.

The open long options position; the SPY June 30th 243 Calls, require \$ 1,010.

when combined with the stock requirement of \$ 79,338

equals \$80,348

which leaves excess cash of \$ 19,652.

These figures are approximate and there might be errors. The trading is hypothetical and we do not count commission costs.

Executions that have occurred at or near the open or close of trading sometimes vary from our actual numbers. For example, when something opens down and it is through our price, we take the next trade whether it is an uptick or continues lower. This sometimes results in a 50% trade that is slightly above or below the exact number.

Previous Week's Recommendations and Rules for the Market Strategies \$100,000 Portfolio Trading Account

- All options count for about \$ 2,500.00 for model portfolio calculations unless otherwise stated
- When the option has doubled sell half the position
- Stop Loss protection is either half or offered with each trade

- The cost of the option is the asking price (or the price between the bid and ask, whichever is more realistic)
- The options will be followed until closed out.
- Option Symbols are stock symbol with expiration month and strike price
-

Option	Cost	Date	Sold	Date	Profit/ (Loss)
SPY June 23 rd 242.50 20 lots	Puts 0.76	06/23/17	0.27	Expired Worthless	\$ 540
SPY June 23 rd 243 20 lots	Calls 0.16	06/23/17	0.50 Sold 10 0.29 Sold 10	06/23/2017	\$ 340 \$ 230
SPY June 243.50 20 lots	Calls 0.32	06/22/17	0.30	06/22/2017	(\$ 40)
TJX July 75	Calls 0.85	06/14/17	0.45	06/19/2017	(\$ 480)

Recommendations will be both listed in this letter and texted to members.

Previous closed out stock and option positions can be found in past Market Strategies Newsletter issues available in the VIP Subscribers Members Area.

Market Strategies Cycles

According to the Stock Trader's Almanac, July may be the best performing month of the third quarter, but the usual mostly negative results that occur in August and September make the comparison easy. Two "hot" Julys in 2009 and 2010 where DJIA and S&P 500 both gained greater than 6% and a strong performance in 2013 have boosted July's average gains since 1950 to 1.2% and 1.0% respectively. Such strength inevitability stirs talk of a "summer rally", but beware the hype, as it has historically been the weakest rally of all seasons (page 72, Stock Trader's Almanac 2017).

July often begins NASDAQ's worst four months and is the third worst performing NASDAQ month since 1971, posting a 0.4% average gain. Dynamic trading often accompanies the first full month of summer as the beginning of the second half of the year brings an inflow of new funds. This creates a bullish beginning, a soft week after options expiration and strength towards the end. The market is particularly vulnerable to a set-back, having been pressing consistently to new all-time highs.

July's first trading day is the fourth best performing first trading day of all twelve months with DJIA gaining a cumulative 1010.33 points since 1998. Over the past 21 years, DJIA's first trading day of July has produced gains 81.0% of the time with an average advance of 0.47%. S&P 500 has advanced 85.7% of the time (average gain 0.45%). NASDAQ has been slightly weaker at 76.2% (0.28% average gain). No other day of the year exhibits this amount of across-the-board strength which makes a case for declaring the first trading day of July the most consistently bullish day of the year over the past 21 years.

Trading on the day before and after the Independence Day holiday is often lackluster. Volume tends to decline on either side of the holiday as vacations begin early and finish late. Since 1980, DJIA, S&P 500,

and NASDAQ have recorded net losses on the day after. Russell 2000 is negative on the day before and the day after.

Post-election year Julys rank at or near the top of all post-election year months. DJIA and S&P 500: +2.2%, #1 (since 1953); NASDAQ (since 1973): +3.4% and Russell 2000 (since 1981): +3.1% #2. Delving deeper into this data revealed that many of these past “hot” Julys were preceded by a flat or down first half of the year so there is no guarantee that this July will live up to its historical post-election year record again this year.

Post-Election Year July since 1953				
	Rank	Avg %	Up	Down
DJIA	1	2.2	13	3
S&P 500	1	2.2	10	6
NASDAQ*	2	3.4	9	2
Russell 1K**	2	3.3	5	4
Russell 2K**	2	3.1	7	2

* Since 1973, ** Since 1981

© StockTradersAlmanac.com. All rights reserved.

Undervalued Small Cap Stocks

Lower priced stocks that look to be a buy:

Lower Capitalized Companies with Great Potential

RMS Medical Products (REPR: \$ 0.45)*

“RMS” or the “Company” is pleased to announce the launch of the RMS Freedom Flow Rate Calculator Smart Phone App (available for Android, and iOS). This App is designed to allow customers to more easily configure an RMS infusion system based on the drug being delivered. The App is an easy to use but highly complex calculator which will aid pharmacists, doctors and nurses in determining the proper RMS Precision Flow Rate Tubing™ and RMS HIgh-Flo Subcutaneous Safety Needle Sets™ to be used with either the FREEDOM60® or the FreedomEdge® Syringe Driver Infusion Systems. Nurses and Pharmacists often make critical decisions about flow rates/tubing and needle selections (size and

number of needles to be used for infusion) in order to meet drug delivery protocols and patient desires for time of infusions. This new App will make it very easy to help the patient receive the best care possible.

This RMS Freedom Flow Rate Calculator Smart Phone App was developed for RMS with resources from **ContraCare** GmbH, a leader in Germany for **Contract Management (reimbursement) Services and Managed Care (homecare) solutions**. The App is now available for iOS in the Apple™ Store and Android in the Google™ Play store. Just go to your favorite store and type in RMS Freedom and you will be able to find and download this free user friendly app.

Torsten Kühn, Chief Executive Officer of ContraCare, commented “as a premium service provider in Germany’s health care system, we aim to partner with leading suppliers to provide the best drugs, medical devices and services to our patients while keeping an eye on the cost efficiency of the treatments we provide. The RMS FREEDOM60® system with its durable and reliable syringe driver and high-quality HIgH-Flo™ subcutaneous safety needle sets are exactly the products we needed for immunoglobulin, antibiotic and many other therapies we are providing today. We are glad that the umbrella organization of Germany’s public health insurance confirms the unmet need by approving the RMS FREEDOM60® System for reimbursement.”

Eric Bauer, Chief Operating Officer of RMS commented, “It can take 12 to 14 months to obtain country registration; by partnering with a leading health care provider, that time was cut significantly. Contra Care is an exceptional partner and we could not be more pleased with our relationship. Germany is going to be a great market for our high quality products and our ever expanding product line. RMS continues to be the Global industry leader and create exceptional partnerships around the world to improve patient quality of life.”

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and our latest Freedom Edge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com.

Contra Care GmbH, based in Nuremberg, Germany, is specialized in providing Contract Management (reimbursement) Services and managed Care (homecare) solutions for patients with chronic diseases. The company is certificated in accordance with ISO 9001, ISO 27001, ISO 13485 and licensed as a homecare provider of medical devices and treatment services according to German Social Law (SGB).

Enzo Biochem (ENZ: \$ 11.54)

Enzo Biochem closed the calendar year 2016 at \$6.94 a share. For the year of 2017, it is up 66.3% versus the Dow Jones +8.3%. Enzo's balance sheet closed their first quarter October 31 with \$67 million in cash and current equivalents and complete elimination of debt. Both the Clinical Lab and Life Science divisions ended the year profitably. New products were added to their catalog and litigations have moved ahead leaving them as a plaintiff with 6 lawsuits in the Delaware Court and one in the Manhattan Court.

What do I look for in 2017? The market will be interesting in the first half with the Government transition to a new administration. Abbots Summary Judgement request was denied by the Court but the trial date has yet to be set. At some point the 2nd Court of Appeals will rule on Enzo's appeal on the CT. Courts reversal of the Jury's decision in the Enzo vs. Apalera Case. The market is giving no value, win or lose, to this decision. The stake is \$65 million with no adverse effect if ruled against Enzo. Enzo should again outperform the Dow and S&P in 2017.

Updates on Delaware Litigation

The last earnings report showed a cash position in excess of \$65 million with no debt to speak of and a positive cash flow from their operating divisions. The only cash burn is coming from Litigation expenses and a bit from Research and Development. Litigation in Delaware is on a contingency basis as such Enzo is not on the hook for billable hours. To my knowledge there are 6 suits left after 6 have settled.

When the company gets a 500 million dollar market cap (\$10.63) they will qualify for those Institutions that can't buy microcap stocks. A significant number of Institutions will look to be buyers and with only 47 million shares issued and Institutions already owning 50% and insiders owning 15% that leaves less than 17 million shares in the float.

Pressure Bio Sciences OTCQB: PBIOD (8.00)*

Recently announced the signing of a new CFO Mr. Joseph L. Damasio Jr. Mr. Damasio has over 20 years of finance and accounting experience most recently as Finance Director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over \$ 100 million in global annual sales. Before joining Nelipak, Mr. Damasio held financial positions at CP Bourg, IQEKC, and Kopin Corporation. Mr Damasio was employed by Pressure BioSciences as both accounting manager (2007) and controller (2008) and finally as Vice President of Finance and Administration (2011).

The hiring of Mr Damasio will allow the Company's CEO Mr Richard T Schumacher, who has been the company's interim CFO for the past two years, and who has been a successful serial life sciences entrepreneur with three successful publicly traded companies to his credit, time to focus on critical operational issues in 2017. Some issues to be attended to include a pending up-list to NASDAQ and their stated goal to build a field sales team this year.

PBIO Develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, they have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders.

NEEDS IN MEDICINE: In the world of medicine our dramatically improved ability for early detection or to confirm and refine diagnosis ranging from over a hundred types of cancer to tuberculosis and a hundred other maladies and conditions is "bottlenecked" by 30 year old methods of preparing test samples. Collectively such diagnostic samples exceed a hundred million annually.

NEEDS IN RESEARCH: Globally there are over a half a million medical and pharmaceutical research scientists working in over eighty thousand laboratories who are hampered by the time consuming and outdated methods of preparing test samples.

NEEDS IN FORENSICS: Globally, in millions of cases, swift and sure exoneration of the innocent and / or justice for the guilty is often delayed or even denied because of the ponderous means of preparing and conducting DNA and other forensic testing.

PBIO is focused on solving the challenges of biological sample preparation, a crucial laboratory step performed globally by the biological life sciences research scientists. Sample preparation refers to a wide range of activities that precede most forms of scientific analysis. It is often complex, time-consuming and, in our opinion, one of the most error-prone steps of scientific research. Sample preparation is a ubiquitous laboratory undertaking - the requirements of which drive a large and growing worldwide market. PBIO has developed and patented a novel, enabling technology platform that can control the sample preparation process while improving both efficacy and quality. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called **pressure cycling technology, or PCT,**

uses alternating cycles of hydrostatic pressure between ambient (normal atmosphere) and ultra-high levels i.e., 35,000 pounds per square inch (“*psi*”) or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

The P BIO pressure cycling technology uses proprietary and internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“*DNA*”), ribonucleic acid (“*RNA*”), proteins, lipids and small molecules. Their laboratory instrument, the Barocycler[®], and their internally developed consumables product line, which include Pressure Used to Lyse Samples for Extraction (“*PULSE*”) tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up their **PCT Sample Preparation System (“*PCT SPS*”).**

The P BIO pressure cycling technology takes a unique approach that has the potential for broad use in a number of established and emerging life sciences areas, which include:

- *Biological sample preparation in potentially thousands of research laboratories worldwide working in human, animal, plant, and microbial diseases and disorders - including but not limited to sample extraction, homogenization, and digestion in genomic, proteomic, lipidomic, metabolomic and small molecule study areas;*
- *Pathogen inactivation (useful in vaccine development, infectious disease research, and more);*
- *Protein purification, and in the control of chemical reactions, particularly enzymatic (useful in drug design and development);*
- *and immunodiagnostics (useful in the development and detection of biomarkers).*

INTELLECTUAL PROPERTY

P BIO has secured their technology through fourteen issued United States patents and ten issued foreign patents covering multiple applications of pressure cycling technology in the life sciences field. They also have additional patents pending. Research indicates that Pressure Bio Science, Inc. is the only company globally to have patents in this new science sector.

NightFood, Inc. (NGTF 0. 30)*

Has healthy night-time food specially formulated for nighttime snackers. The Company has an exclusive agreement with RFI, natural ingredient manufacturer and proprietor of Chocamine, a patented cocoa extract which helps with cravings and mood (calmness), and promotes feelings of satiety.

Americans keep gaining more weight. People have the tendency to grab for goodies at the end of the evening as they relax to enjoy some T.V. Eating and snacking too late at night is a contributing factor to gaining weight. Seventy percent of adults, ages 18-54, snack in the hour or two before bed. Chocamine delivers the health benefits of chocolate to the body (amino acids, minerals and polyphenols) without the added sugars, caffeine or fat.

People give in to the intense hunger cravings that leads to the consumption of sugary, salty or calorie dense foods to satisfy their appetite and cravings. Most of the snacks that people typically eat can impair sleep, causing a person to wake up feeling unrested. Night Food offers better-for-you alternatives to high-calorie and sleep disruptive junk foods.

The company product line currently includes snack bars in two flavors, either Cookies and Dreams or Midnight Chocolate Crunch. The company recently reported that it is looking into expanding the number of flavors in the Night Food bar line, and also manufacturing products in different snack formats, like ice cream or “bites”

Consumers spend over \$50 billion/year on night-time snacks...over \$1B every week. In general, snacking trends have shifted much healthier over the past several years, but industry research continues to show that the least healthy choices of the day occur as we get closer to bedtime. In fact, the four most popular nighttime snack categories, in order, are salty snacks (chips, pretzels, popcorn), ice cream, chocolate candy, and cookies,

Management believes that, just as there are energy versions of many popular foods (energy jerky, energy candy, energy waffles, energy gum, energy chips, energy bars), foods can also be formulated to be more nighttime appropriate and sleep-friendly.

We've seen it happen with low-carb, we've seen it happen with gluten-free. Can it happen with nighttime snacking as well?

Leo Motors (LEOM: \$ 0.11)*

has patents for the electric battery industry which we will be writing about in upcoming weekly reports. They have developed a lithium battery that can operate vehicles in sub-zero climates. Their subsidiary LGM has developed battery technology supported by the Korean government to make it possible to use electric battery technology for fishing boats. They have a cartridge system which is a light-weight replacement method of swapping electric batteries.

Fishing has been harmed by the noise and oil leaks from internal combustion engines. LGM has solved that problem and besides eliminating the toxic problem, operating costs are reduced by 25%.

In addition they have a special patent for averting electric hazards and shocks. Leo developed the Internet of Things for e-boats which is networked and connected with an Android Operating System. Leo's power supply system is CAN (Controller Area Network) based, which enables mobile diagnostics between mobile devices and boats using the Leo technology.

Leo is developing a battery swap system for Kalmado in Puerto Princesa, Philippines, a world famous tourist attraction, which is focused on green energy. They will be converting 100 boats as the environment is expected to become 100% free of the toxicity from internal combustion engines. Also, Leo has developed a battery swap system for Go-Karts to be used in malls in China, Korea and Myanmar. Leo Motors has a new carbon nanotube battery power pack that functions and supplies full power in extreme low temperatures such as below 49 degrees without the need for grid electricity.

Skinvisible (SKVI: \$ 0.025)*

Skinvisible Pharmaceuticals, Inc., (OTCQB: SKVI), is a pharmaceutical technology company that has developed over 40 topical prescription (Rx), over-the-counter (OTC) and cosmeceutical products using its patented Invisicare® polymer delivery systems. Invisicare and its products are protected by fourteen patents worldwide. Skinvisible licenses these products to global pharmaceutical, cosmetic and consumer goods companies.

SKINVISIBLE ENTERS THE CANNABIS MARKET

The cannabis market that Skinvisible has entered is vast and one of the fastest growing markets. The legal marijuana industry (medical and recreational) in the USA has reached over \$6 billion in annual sales and is expected to increase to over \$20 billion by 2020. Canada is projected to reach up to \$22 billion annually as it has passed both medical and recreational marijuana laws this past year. Skinvisible is perfectly poised to be a part of this expanding market. It is part of the ancillary cannabis market as Skinvisible does not sell or touch cannabis; it sells its proprietary Invisicare polymers coupled with proven product formulations and services to its licensees. Skinvisible will help bring science-based, patent protected products into this emerging industry. The Company has developed topical and transdermal cannabis products from hemp-derived CBD; with its next developments to include cannabinoids from marijuana (CBD and THC).

SKINVISIBLE RECEIVES FIRST ORDER FOR CHINA

The Company just recently announced that it has completed its first international sale of DermSafe® hand sanitizer through its agent InterSpace Global, Inc. (“InterSpace”). InterSpace is an exporter of “made in USA” products with offices in Salt Lake City, Utah and Shenzhen, China. InterSpace has completed its first sale of DermSafe® with a direct sales company in Shanghai, China. Skinvisible management attended the launch of DermSafe in Shanghai, China, with 1200+ distributors in attendance. China with a population of over 1.4 billion people is one of the fastest growing economies in the world and represents a huge market for Skinvisible products, not only for DermSafe hand sanitizer but also the OTC line of products including anti-aging skincare line.

Rule 17B Attestations and Disclaimers

Princeton Research, Inc. has approximately 2,581,578 shares of AIVN both free and restricted and represents them for Investor relations. Princeton also has about 40,000 shares of TXGE. Princeton is paid \$ 1,500 per month from RMS Medical Products. Princeton has bought 81,100 shares of RMS Medical Products. Princeton was paid \$ 2,500 to write a report on Xinergy. Princeton has signed a contract with CBLI to be paid \$ 2500 for July and August for investor relations. Princeton has been engaged by Target Energy. No contract is currently in place. Princeton was paid about 500,000 restricted shares of Leo Motors.

When there is no movement in penny stocks, even though there is none or very small losses, we will liquidate (sold AIVN on stop) even though we like the company, if money is needed for better opportunities.

We now believe REPR represents upside opportunity. The Target ADR trades at about \$ 4.50 in U.S. vs 0.05 in Australia. Princeton owns 400,000 Australia shares and about 900 U.S. ADR's.

Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this e-mail issue. Princeton may buy or sell its free-trading shares in companies it represents at any time.

CONTACT

Please Direct All Inquiries To:

Mike King
(702) 650-3000
mike@princetonresearch.com

Charles Moskowitz
(781) 826-8882
CAM@MoneyInfo-LLC.com

Princeton Research
3887 Pacific Street,
Las Vegas, Nevada 89121

Fax: (702) 697-8944

www.PrincetonResearch.com